Posted by Michael Wonder on 28 Nov 2018
Octapharma receives Swissmedic approval for fibryga to treat congenital and acquired fibrinogen deficiencies
26 November 2018 - Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorisation to its new fibrinogen concentrate product fibryga for the treatment of congenital and acquired fibrinogen deficiencies.
This approval is an important achievement for the company and most importantly, represents major progress for patients and physicians.
Fibryga is a lyophilised fibrinogen concentrate for intravenous infusion, produced from pooled human plasma.
